Condition

NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials and research

• 28Clinical trials
• 1New in 30 days
• 24Countries

Newest NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials

All recruiting trials (28)

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• AMT-116 vs doctor’s choice in advanced non-squamous NSCLC that is EGFR-wild and progressed after platinum and PD-1/PD-L1 therapy

  This study tests AMT-116 in adults with advanced non-squamous NSCLC that is EGFR-wild, comparing different doses to doctor’s choice after prior platinum and immunotherapy.

  Recruiting Phase 2/3 Multitude Therapeutics Inc. · Port Saint Lucie, Florida and 6 other locations · NCT07718737

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Two-part Phase 1/2 test of ODM-212 combined with other cancer treatments

  This trial tests the oral drug ODM-212, given alone or with approved medicines, to see if it helps adults with advanced mesothelioma, pancreatic cancer, or non-small cell lung cancer.

  Recruiting at 23 sites Phase 1/2 Orion Corporation, Orion Pharma · Los Angeles, California and 22 other locations · NCT07563738

• Vebreltinib with Platinum Chemotherapy as First-line Treatment for MET-Overexpressing NSCLC

  This study tests whether adding vebreltinib to platinum-based chemotherapy can help adults with advanced NSCLC that overexpress MET and lack driver mutations respond to treatment as a first option.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07549061

• Microwave ablation plus tislelizumab and docetaxel for advanced NSCLC after first-line immunotherapy progression

  This treatment tests whether adding microwave ablation to tislelizumab and docetaxel can help people with advanced non‑small cell lung cancer whose disease progressed after first‑line immunotherapy plus chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07528274

• Long-term outcomes after first-line tislelizumab plus chemotherapy in advanced squamous NSCLC

  This project collects long-term survival data from people with advanced squamous non-small cell lung cancer who received first-line tislelizumab plus chemotherapy in RATIONALE-307 to see who benefited most.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07478809

• TCC1727 combined with other cancer medicines for adults with advanced solid tumors

  This phase Ib/II trial tests TCC1727 given with benmelstobart, olaparib, or topotecan in adults with advanced solid tumors to find safe doses and see if the combinations help control tumors.

  Recruiting Phase 1/2 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 2 other locations · NCT07371663

• HJ-004-02 tablets for advanced non-squamous EGFR-mutant non-small cell lung cancer

  This trial tests whether daily HJ-004-02 tablets are safe, how the body processes them, and whether they have anti-tumor activity in adults with advanced non-squamous non-small cell lung cancer that has EGFR mutations and progressed after standard treatments.

  Recruiting Phase 1 Tongji University · Shanghai, Shanghai Municipality · NCT07361237

• Tracking HER2 mutations and treatment patterns in advanced non-small cell lung cancer in Italy

  This project will see how people in Italy with advanced NSCLC and HER2 mutations are diagnosed and treated over a one-year follow-up period.

  Recruiting at 2 sites Gruppo Oncologico Italiano di Ricerca Clinica · Bari, BA and 21 other locations · NCT07356544

• Pulsatile high-dose furmonertinib for EGFR-mutant NSCLC with leptomeningeal metastasis

  This tests whether taking high-dose furmonertinib every other day helps people with EGFR-mutant non-small cell lung cancer that has spread to the leptomeninges.

  Recruiting Guangzhou University of Traditional Chinese Medicine · Guangzhou, Guangdong · NCT07348965

• QL1706 plus chemotherapy for immune-resistant advanced NSCLC

  This trial tests whether adding QL1706 to chemotherapy helps people with advanced non-small cell lung cancer who are EGFR/ALK negative and whose cancer progressed after prior PD‑1/PD‑L1 plus platinum therapy.

  Recruiting Phase 2 Anhui Provincial Cancer Hospital · Hefei · NCT07330596

• How gene changes relate to clotting risk in advanced or metastatic non-small-cell lung cancer

  This project will test whether specific cancer gene changes are linked to blood-clotting markers and the risk of venous blood clots in people with advanced non-small-cell lung cancer.

  Recruiting University Of Perugia · Perugia, Perugia · NCT07288632

• CEA-targeted CAR-T therapy for advanced CEA-positive solid tumors

  This trial will try a CEA-targeted CAR-T cell therapy in adults with advanced, CEA-positive non-small cell lung cancer or breast cancer who have progressed after standard treatments.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07250386

• Gemcitabine plus Ivonescimab for advanced NSCLC that progressed after immunotherapy

  This trial tests whether combining gemcitabine with ivonescimab can help people with advanced NSCLC whose cancer has grown after prior chemo-immunotherapy.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Baden and 7 other locations · NCT07158489

• EMPATHY NSCLC: European registry of blood-based molecular profiling in advanced NSCLC

  This registry will collect real-world data to see if blood (plasma) and tissue molecular profiling help guide first-line treatment and outcomes for people starting therapy for advanced non-small cell lung cancer.

  Recruiting at 3 sites Hedera Dx SA · Nancy, Lorraine and 3 other locations · NCT07096258

• ALX2004 for advanced or metastatic EGFR-expressing solid tumors

  This trial will test ALX2004, an antibody-drug conjugate that targets EGFR, in people with advanced or metastatic non-small cell lung, head and neck, esophageal, or colorectal cancer to see if it is safe and shows tumor activity.

  Recruiting at 11 sites Phase 1 ALX Oncology Inc. · La Jolla, California and 11 other locations · NCT07085091

• Oral pooled fecal microbiotherapy (MaaT033) with cemiplimab to try to reverse antibiotic-related resistance in advanced NSCLC

  This trial will try whether taking an oral pooled fecal microbiotherapy (MaaT033) together with cemiplimab can restore response to immunotherapy in adults with advanced non-small cell lung cancer who became resistant after taking antibiotics.

  Recruiting at 3 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Dijon and 5 other locations · NCT07001618

• Trilaciclib given before sacituzumab tirumotecan to protect bone marrow in EGFR-mutated advanced NSCLC

  This trial will test whether giving trilaciclib before sacituzumab tirumotecan helps protect the blood and reduce blood-related side effects in people with advanced EGFR‑mutated non-small cell lung cancer who have stopped responding to EGFR-TKI therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06992739

• Golidocitinib plus tislelizumab and chemotherapy for first-line advanced NSCLC

  This phase 1 trial will try adding golidocitinib to tislelizumab and chemotherapy to see if people with advanced NSCLC and PD-L1 ≥1% can live longer without their cancer getting worse.

  Recruiting Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06969612

• Comparing firmonertinib to chemotherapy for advanced lung cancer with specific mutations

  This study is testing whether a new drug called firmonertinib can work better than standard chemotherapy for people with advanced lung cancer who have specific genetic mutations.

  Recruiting at 2 sites Phase 3 Allist Pharmaceuticals, Inc. · Beijing, Beijing Municipality and 1 other locations · NCT06956001

• JMKX001899 combined with IN10018 and/or chemotherapy for advanced KRAS G12C non-small cell lung cancer

  This trial will test whether the experimental drug JMKX001899, given alone or with IN10018 and/or chemotherapy, is safe and shows signs of benefit for people with advanced non-small cell lung cancer that has the KRAS G12C mutation.

  Recruiting Phase 1 Jemincare · Guangzhou, Guangdong · NCT06946927

• Inhaled cisplatin for treating advanced lung cancer

  This study is testing if inhaling a new form of chemotherapy can help people with advanced lung cancer live longer and feel better while reducing side effects from traditional treatments.

  Recruiting at 11 sites Phase 1/2 Inhatarget Therapeutics · Brussels and 14 other locations · NCT06896890

• Evaluating daraxonrasib for previously treated patients with RAS mutated lung cancer

  This study is testing if a new drug called daraxonrasib can help people with RAS mutated lung cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 26 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 198 other locations · NCT06881784

• ORIENT-31 plus targeted SBRT for EGFR‑mutant metastatic lung cancer after third‑generation EGFR‑TKI

  This study will test whether adding targeted stereotactic radiotherapy (SBRT) to the ORIENT-31 drug combination helps people with EGFR‑mutant metastatic non‑small cell lung cancer whose disease progressed after first‑line third‑generation EGFR‑TKIs.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06775743

• Treatment for advanced non-small cell lung cancer with specific mutations

  This study is testing a new oral medication called BH-30643 to see if it can safely help people with advanced non-small cell lung cancer that has specific mutations.

  Recruiting at 43 sites Phase 1/2 BlossomHill Therapeutics · Phoenix, Arizona and 42 other locations · NCT06706076

• Using AI to predict treatment outcomes in lung cancer patients with brain metastases

  This study is testing if using artificial intelligence to look at brain and lung scans can help predict how well treatment will work for people with advanced lung cancer that has spread to the brain.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06604689

• Evaluating a new treatment for advanced solid tumors

  This study is testing a new treatment called ADU-1805 for people with advanced solid tumors to see how safe it is and how well it works on its own and with another drug.

  Recruiting at 11 sites Phase 1 Sairopa B.V. · Detroit, Michigan and 10 other locations · NCT05856981

Related topics

Quick answers

How many NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials are recruiting right now?

28, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in China (14 trials), United States (8 trials), France (5 trials), Spain (5 trials), Italy (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 8, Phase 2: 7, Phase 1/2: 4, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →